Project Details
Description
In this STTR Phase I application, the Hu laboratory at UTMB partners with the biotech startup company, RNA Therapeutics Inc, to submit a proposal that aims to further develop a pan COVID-19 mRNA vaccine candidate. The work to be conducted at UTMB include animal (hamster) vaccination and SARS-CoV-2 challenge to evaluate protective efficacy of the vaccines in animal models.
| Status | Finished |
|---|---|
| Effective start/end date | 1/1/00 → 1/1/00 |
Funding
- RNA Therapeutics, Inc ( Award #1R41AI18113401): $179,999.59
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.